2024
Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy
Akiyama S, St-Pierre J, Traboulsi C, Silfen A, Rai V, Rodriguez T, Erondu A, Steinberg J, Shaffer S, Christensen B, Rubin D. Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy. Npj Gut And Liver 2024, 1: 5. DOI: 10.1038/s44355-024-00005-9.Peer-Reviewed Original ResearchHistologic normalizationUlcerative colitisDe-escalationUC patientsDe-escalation of therapyTherapeutic de-escalationMedian follow-upDe-escalation groupProportion of patientsStudy assessed outcomesHistological recurrenceRecurrence rateSingle-centerClinical stabilityTherapeutic changeRemission outcomesFollow-upTherapyPatientsImmunomodulationAminosalicylatesWithdrawalColitisMonthsOutcomes
2022
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai P, Rai V, Raffals L, Lukin D, Hudesman D, Kochhar G, Damas O, Sauk J, Levy A, Sofia M, Tuskey A, Deepak P, Yarur A, Afzali A, Ananthakrishnan A, Cross R, Hanauer S, Siegel C. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American Journal Of Gastroenterology 2022, 117: 1288-1295. PMID: 35416799, PMCID: PMC9437635, DOI: 10.14309/ajg.0000000000001775.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsModerate-severe flaresUlcerative colitisAntitumor necrosis factor therapyModerate-severe ulcerative colitisNecrosis factor therapyRAND appropriateness panelMethylprednisolone 40Naive patientsPostdischarge managementSteroid dosingStool frequencyRectal bleedingTherapy initiationAdverse eventsFactor therapyInpatient managementPostdischarge careHospital admissionLower endoscopyDischarge planningLower riskPatientsDischarge criteriaAppropriate managementHigh dosesHistopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis
Akiyama S, Ollech J, Traboulsi C, Rai V, Glick L, Yi Y, Runde J, Olivas A, Weber C, Cohen R, Olortegui K, Hurst R, Umanskiy K, Shogan B, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Hart J, Hyman N, Rubin D. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Digestive Diseases And Sciences 2022, 67: 4020-4031. PMID: 35288827, PMCID: PMC10966959, DOI: 10.1007/s10620-022-07405-y.Peer-Reviewed Original ResearchConceptsIleal pouch-anal anastomosisUlcerative colitisColectomy specimensTerminal ileal involvementCrohn's diseaseIleal involvementPouch fistulaFocal inflammationDeep inflammationLimb involvementPouch-anal anastomosisLogistic regression analysisIleostomy takedownPouch bodyPouch lossEndoscopic appearancePathology reviewMultivariable analysisHistologic featuresPoor prognosisPathological dataEndoscopic phenotypesHigh riskPatientsInflammationOutcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis
Runde J, Erondu A, Akiyama S, Traboulsi C, Rai V, Glick L, Yi Y, Ollech J, Cohen R, Skowron K, Hurst R, Umanskiy K, Shogan B, Hyman N, Rubin M, Dalal S, Sakuraba A, Pekow J, Chang E, Rubin D. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch–Anal Anastomosis in Pediatric Ulcerative Colitis. Inflammatory Bowel Diseases 2022, 28: 1386-1394. PMID: 35040964, PMCID: PMC9434476, DOI: 10.1093/ibd/izab319.Peer-Reviewed Original ResearchConceptsIleal pouch-anal anastomosisPediatric ulcerative colitisPouch-anal anastomosisUlcerative colitisYears of agePouch survivalAdult patientsRetrospective single-center studyIleoanal pouch anastomosisAnti-TNF therapySingle-center studyKaplan-Meier curvesLog-rank testKaplan-Meier estimatesPediatric control subjectsElectronic medical recordsChi-square testPouch anastomosisPouch failureTotal proctocolectomyPediatric patientsSurgical outcomesControl subjectsMedical recordsRapid progression
2021
Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia
Shaffer S, Erondu A, Traboulsi C, Rai V, Cleveland N, Israel A, Christensen B, Rubin D. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflammatory Bowel Diseases 2021, 28: 553-559. PMID: 34037230, PMCID: PMC9122749, DOI: 10.1093/ibd/izab130.Peer-Reviewed Original ResearchConceptsPersistent histologic activityHistologic normalizationUlcerative colitisHistologic activityUC diagnosisSubsequent dysplasiaIncidence rateDysplasia developmentDiagnosis of UCCox regression analysisKaplan-Meier graphsImproved clinical outcomesDevelopment of dysplasiaHistologic inflammationUC durationDysplasia ratesDisease courseTertiary centerClinical outcomesDecreased riskPatient groupSurveillance intervalsHistologic assessmentRetrospective analysisReduced riskA Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis.
Rubin D, Traboulsi C, Rai V. A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. Gastroenterology & Hepatology 2021, 17: 59-66. PMID: 34035764, PMCID: PMC8132723.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsUlcerative colitisDisease activityRecurrent disease activityLong-term remissionManagement of patientsGoal of treatmentPractical clinical approachPatient's risk levelRange of symptomsAbdominal painRectal bleedingFulminant diseasePrognostic factorsSurgical optionsTherapeutic choiceInpatient settingPatientsClinical approachDrug mechanismsDisease responseRemissionColitisTreatmentObjective measuresCritical appraisal
2020
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
Rubin D, Abreu M, Rai V, Siegel C, Disease I, Ahuja V, Allez M, Ananthakrishnan A, Bernstein C, Braun J, Chowers Y, Colombel J, Danese S, D'Haens G, D'Hoore A, Dignass A, Dotan I, Dubinsky M, Ekbom A, Fleshner P, Gassull M, Gearry R, Ghosh S, Griffiths A, Halfvarson J, Hanauer S, Harpaz N, Hart A, Kamm M, Kaplan G, Koutroubakis I, Lakatos P, Levine A, Lewis J, Lindsay J, Loftus E, Louis E, Lukas M, Magro F, Mahadevan U, Mantzaris G, McGovern D, Moum B, Munkholm P, Neurath M, Ng S, O'Morain C, Panaccione R, Panes J, Peyrin-Biroulet L, Prantera C, Ran Z, Reinisch W, Remzi F, Sachar D, Sandborn W, Sartor R, Schölmerich J, Schreiber S, Siegmund B, Silverberg M, Söderholm J, Stange E, Steinwurz F, Turner D, Vatn M, Vermeire S, Brenner E, Christensen B, D'Amico F, Griffiths C, Higgins P, Kappelman M, Lees C, Regueiro M, Rosh J, Ungaro R. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology 2020, 159: 6-13.e6. PMID: 32272113, PMCID: PMC7194599, DOI: 10.1053/j.gastro.2020.04.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsManagement of patientsUlcerative colitisCrohn's diseaseCoronavirus diseaseDiseaseInternational meetingsColitisPatientsRe: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial
Akiyama S, Traboulsi C, Rai V, Rubin D. Re: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2247-2247. PMID: 32242252, DOI: 10.1007/s00259-020-04774-2.Commentaries, Editorials and LettersCumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study
Yvellez O, Rai V, Sossenheimer P, Hart J, Turner J, Weber C, Jurdi K, Rubin D. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflammatory Bowel Diseases 2020, 27: 203-206. PMID: 32152624, PMCID: PMC7813748, DOI: 10.1093/ibd/izaa047.Peer-Reviewed Original ResearchConceptsCumulative inflammatory burdenDevelopment of CRNHistological inflammatory activityColorectal neoplasiaUC patientsUlcerative colitisCRN patientsHistologic inflammationSurveillance intervalsRisk of CRNLow-grade dysplasiaMaximum severitySt. Mark's HospitalCase-control cohortInflammatory burdenInflammatory indexDisease durationInflammatory activityChronic inflammationIndefinite dysplasiaColorectal cancerSurveillance episodesPatientsInflammationMean severity
2019
Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis
Ollech J, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer P, Christensen B, Pekow J, Dalal S, Sakuraba A, Cohen R, Rubin D. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis. Alimentary Pharmacology & Therapeutics 2019, 51: 637-643. PMID: 31875986, DOI: 10.1111/apt.15616.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedCalcineurin InhibitorsColitis, UlcerativeDrug Administration ScheduleDrug ResistanceFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexSteroidsTreatment OutcomeYoung AdultConceptsSevere steroid-refractory ulcerative colitisSteroid-refractory ulcerative colitisCalcineurin inhibitorsInduction therapyMaintenance therapyUlcerative colitisVedolizumab initiationMedian timeWeek 14Colectomy-free survival ratesSevere steroid-refractory colitisColectomy-free survivalSteroid-refractory colitisVedolizumab maintenance therapyInduction of remissionSerious adverse eventsSevere ulcerative colitisRetrospective observational studyEnd of inductionBiochemical remissionVedolizumab discontinuationClinical remissionPrimary endpointSecondary endpointsAdult patientsFollow-Up of Patients With Ulcerative Colitis and Histological Normalization
Israel A, Christensen B, El Jurdi K, Rai V, Ollech J, Cohen R, Sakuraba A, Dalal S, Rubin D. Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clinical Gastroenterology And Hepatology 2019, 18: 987-988.e1. PMID: 31228567, PMCID: PMC6923607, DOI: 10.1016/j.cgh.2019.06.025.Peer-Reviewed Original ResearchConceptsUlcerative colitisManagement of UCSpecific treatment goalsEndoscopic improvementHistological normalizationDisease activityMucosal injuryRemitting courseHistological endpointsTreatment goalsNatural historyColitisMicroscopic featuresUnanswered questionsInflammationPatientsChronicityMucosaInjuryHistologyDiagnosisEndpoint